empagliflozin + potassium chloride

Empagliflozin + potassium chloride is an experimental drug combination being evaluated by the University of Pennsylvania in the SAK HFpEF Trial (NCT05138575). This combination serves as an active control arm in a randomized crossover study investigating the effects of SGLT2 inhibition and inorganic nitrate on exercise endurance and skeletal muscle mitochondrial function in patients with heart failure with preserved ejection fraction (HFpEF). Empagliflozin is a small molecule inhibitor of the sodium-glucose cotransporter-2 (SGLT2), which promotes glucose and sodium excretion in the kidneys to improve cardiovascular outcomes. In this specific trial context, potassium chloride is administered alongside empagliflozin to serve as a control for the potassium nitrate arm, allowing researchers to isolate the effects of the nitrate component on submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity.

Other names

Empagliflozin + KCl